SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at three upcoming investor conferences:
-- BIOCOM Investor Conference to be held at the Hyatt Regency in La Jolla, Calif. on Monday, October 27, 2008 at 2:00 p.m. PDT (5:00 p.m. EDT);
-- Oppenheimer's 19th Annual Healthcare Conference to be held at the Waldorf-Astoria Hotel in New York on Monday, November 3, 2008 at 10:40 a.m. EST (7:40 a.m. PST); and
-- Lazard Capital Markets 5th Annual Healthcare Conference to be held at the St. Regis Hotel in New York on Tuesday, November 18, 2008 at 2:40 p.m. EST (11:40 a.m. PST).
Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation dates.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing
products targeting the extracellular matrix for the drug delivery,
metabolism, oncology, and dermatology markets. The company's portfolio of
products and product candidates is based on intellectual property covering
the family of human enzymes known as hyaluronidases. The company's
Enhanze(TM) Technology is a novel drug delivery platform designed to
increase the absorption and dispersion of biologics. Its key partnerships
are with Roche to apply Enhanze Technology to Roche's biological
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved